Target intelligence / Profile preview

Voltage-gated potassium channel subunit Kv1.5 (Kv1.5 channel)

Target
Kv1.5 channel
Molecular classification
Ion channel, Voltage-gated potassium channel, Shaker-type (Kv1 subgroup)
01

Overview

Voltage-gated potassium channel subunit Kv1.5 is a membrane protein responsible for conducting the ultra-rapid delayed rectifier K(+) current (I~Kur~), critical for atrial repolarization in the human heart. Structurally, each channel is formed by four pore-forming α-subunits comprising six transmembrane segments (S1–S6); the selectivity filter within the pore region enables potassium ion selectivity. Kv1.5 channels are selectively expressed in atrial rather than ventricular myocytes, making them an attractive target for atrial-selective antiarrhythmic agents to treat atrial fibrillation without triggering ventricular proarrhythmia. Genetic mutations in the KCNA5 gene are linked to familial atrial fibrillation, and alterations in Kv1.5 channel function are implicated in various cardiovascular and oncological pathologies. Drug development faces challenges due to selectivity and variable expression, with both small molecules (e.g., vernakalant) and peptides explored as therapeutic modulators.

Other names
Kv1.5KCNA5Shaker-related voltage-gated potassium channelI~Kur~ channel
02

Mechanism of action

Open-channel block (many inhibitors act by blocking the channel when open); Selective inhibition of I~Kur~ current; Peptide toxin binding (increased selectivity and affinity compared to small molecules)

03

Biological functions

Repolarization of atrial action potentialRegulation of vascular tonePotassium ion transportControl of cellular excitability
04

Disease associations

Cardiovascular disease (atrial fibrillation, arrhythmia)Cancer (various types, via aberrant expression in tumors)
05

Safety considerations

Off-target cardiac arrhythmias (e.g., proarrhythmias, action potential shortening, torsade de pointes risk)Limited selectivity leading to side effectsChanges in pharmacological response due to tissue remodeling in chronic AF
06

Interacting drugs

Vernakalant

4 more in the full profile.

07

Biomarkers

KCNA5 gene mutation status (hereditary atrial fibrillation)Kv1.5 protein expression in atrial tissue (for patient selection in AF therapy)

Beyond the preview

Go deeper on Voltage-gated potassium channel subunit Kv1.5 (Kv1.5 channel).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Voltage-gated potassium channel subunit Kv1.5 (Kv1.5 channel).

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call